NEW YORK ( TheStreet) -- InterMune (Nasdaq: ITMN) is trading at unusually high volume Thursday with 5.1 million shares changing hands. It is currently at 4.2 times its average daily volume and trading down $2.63 (-14.4%) at $15.66 as of 11 a.m. ET.

InterMune has a market cap of $1.21 billion and is part of the health care sector and drugs industry. Shares are down 49.4% year to date as of the close of trading on Wednesday.

InterMune, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies in pulmonology and fibrotic diseases. The company has a P/E ratio of 9.5, below the average drugs industry P/E ratio of 10.2 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates InterMune as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and generally poor debt management. You can view the full InterMune Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.
null

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000